Phase 3: Epcoritamab Combo Cuts DLBCL Progression Risk by 60%
Key Takeaways
- A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Mentioned
Key Intelligence
Key Facts
- 1Epcoritamab + lenalidomide reduced the risk of disease progression or death by 60% vs. R-GemOx in U.S. analysis (HR 0.40, 95% CI 0.30–0.55, p<0.0001), and by 56% in ex-U.S. analysis (HR 0.44, 95% CI 0.33–0.60, p<0.0001).
- 2The global Phase 3 EPCORE DLBCL-4 trial enrolled adults with relapsed/refractory DLBCL who had received at least one prior systemic therapy.
- 3The combination’s safety profile was consistent with the known profiles of epcoritamab and lenalidomide individually, according to the companies.
- 4Epcoritamab is a subcutaneous, fixed-duration, T-cell engaging bispecific antibody targeting CD3 and CD20.
- 5The comparator arm was rituximab plus gemcitabine and oxaliplatin (R-GemOx), a standard salvage chemoimmunotherapy regimen.
- 6AbbVie and Genmab will engage global regulatory authorities to discuss next steps toward potential label expansion.
Risk of progression or death vs. R-GemOx in Phase 3 EPCORE DLBCL-4
Today's encouraging topline results highlight the potential of epcoritamab, a fixed-treatment therapy, in combination with lenalidomide, as a meaningful treatment option after initial disease progression.
Press release
Analysis
- Massive 60% PFS improvement over standard salvage chemo
- Fixed-duration, subcutaneous + oral administration enhances patient quality of life
- Safety consistent with known profiles, avoiding many chemo toxicities
- Full safety and secondary endpoint data not yet disclosed
- Regulatory approval and real-world adoption timelines may extend 1–2 years
- Competing CAR-T and bispecific options may limit market share despite positive data
Analysis
For health systems and payers, the rising cost and complexity of cancer care demand therapies that deliver both superior outcomes and manageable infrastructure requirements. The reported 60% reduction in disease progression risk with a subcutaneous antibody–pill doublet challenges the traditional reliance on intensive salvage chemotherapy for DLBCL, signaling a shift that could reduce hospitalizations, lower supportive care needs, and improve patient convenience—all while potentially easing the burdens on infusion centers and oncology staff.
On June 29, 2026, AbbVie and Genmab announced topline results from the pivotal Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of the T-cell engaging bispecific antibody epcoritamab and the immunomodulatory agent lenalidomide achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard-of-care regimen rituximab plus gemcitabine and oxaliplatin (R-GemOx) in adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who had received at least one prior line of therapy. According to the companies, the risk of disease progression or death was reduced by 60% under U.S. censoring rules (hazard ratio [HR] 0.40; 95% CI 0.30–0.55; p<0.0001) and by 56% under ex-U.S. censoring (HR 0.44; 95% CI 0.33–0.60; p<0.0001). The safety profile of the combination was consistent with the known profiles of each drug.
censoring rules (hazard ratio [HR] 0.40; 95% CI 0.30–0.55; p<0.0001) and by 56% under ex-U.S.
This announcement marks a significant milestone for the epcoritamab program, which already holds approvals in later lines of DLBCL and follicular lymphoma. The EPCORE DLBCL-4 trial targets a patient population with limited effective options, often facing aggressive disease and poor outcomes after initial treatment failure. R-GemOx, the comparator, is a widely used salvage chemoimmunotherapy regimen, but it offers modest efficacy and significant toxicity. The dramatic PFS benefit reported for the non-chemotherapy doublet represents a potential paradigm shift, substituting chemotherapy with a targeted, fixed-duration immunotherapy approach.
The context is a rapidly evolving treatment landscape for B-cell lymphomas. Epcoritamab, a subcutaneous CD3xCD20 bispecific, belongs to a class that has recently transformed hematological oncology. Competitors include glofitamab (Roche) and mosunetuzumab (Genentech), but epcoritamab’s versatility as a combination partner is a key differentiator. Lenalidomide, an immunomodulatory drug often used in lymphomas, likely potentiates T-cell and NK-cell antitumor activity, complementing epcoritamab’s mechanism. The fixed-duration design (epcoritamab given for a defined period) may offer advantages in reducing treatment burden, limiting cumulative toxicities, and potentially lowering long-term costs compared to indefinite therapies or complex CAR-T infusions.
What to Watch
The implications for AbbVie and Genmab are substantial. Epcoritamab is co-commercialized globally; AbbVie leads in the U.S. and Japan, while Genmab leads in Europe. Expansion into earlier lines of therapy would significantly broaden the addressable patient population – an estimated 30,000 new DLBCL cases are diagnosed annually in the U.S., with a substantial proportion relapsing after first-line treatment. Positive data from a Phase 3 trial with a robust hazard ratio positions the combination for regulatory submissions. Both companies stated they will engage global regulators to discuss next steps. The overarching goal is to move epcoritamab-based regimens into the second-line setting, competing not only with other bispecifics but also with CAR-T therapies, which, while highly effective, are logistically complex and expensive. The lenalidomide combination, with a favorable oral-plus-subcutaneous administration profile, could capture a broad segment of patients who are not candidates for or do not have immediate access to CAR-T.
Looking forward, investors and clinicians will watch for full data presentation at a future medical meeting, where key secondary endpoints like overall survival, response rates, and quality of life will be scrutinized. Regulatory pathways may include a supplemental Biologics License Application in the U.S. and similar submissions in Europe, with potential approval timelines of 12–18 months. The combination’s safety consistency reassures, but detailed adverse event profiles are needed to assess manageability in real-world practice. Meanwhile, AbbVie and Genmab are conducting multiple epcoritamab combination trials, aiming to establish the drug as a backbone therapy across B-cell malignancies. Success in DLBCL would not only strengthen the franchises of both companies but also validate the broader thesis that bispecific antibodies can replace traditional chemotherapy in hematological cancers, ultimately improving patient outcomes and reshaping treatment guidelines.
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |